Remus Pharmaceuticals Limited
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
What Remus files
- Others54
- Investor Meet16
- Important11
- Board Meeting11
- Updates9
- Dividend/Bonus8
REMUS's RTA, MUFG Intime India, has updated its investor communication email to investor.helpdesk@in.mpms.mufg.com. Electronic shareholder queries must now be submitted via the RTA's website helpdesk. Other RTA details are unchanged.
REMUS has successfully incorporated its new subsidiary, Espee Global Clinical Trial Services Private Limited. This marks a significant business development, officially establishing the entity under the Companies Act. This expansion builds on the previously announced approval, enhancing the company's operational capabilities and potential for future growth in clinical trial services.
Remus Pharmaceuticals has announced a board meeting to approve the incorporation of a new wholly-owned subsidiary, Espee Global Clinical Trial Services Pvt. Ltd., focused on clinical trial material management and related services. The subsidiary will address growing demand for compliant clinical trial support in India and globally. The initial investment...
Remus Pharmaceuticals has announced a board meeting to discuss material events and disclosures. Key managerial personnel, including the MD, WTD, and CFO, have been designated to assess the significance of events and oversee communication. The Company Secretary will manage stock exchange filings. No operational or financial impact was indicated.
Remus Pharmaceuticals has announced a board meeting to appoint Sharp & Tannan Associates as internal auditor for FY 2025-26. The firm’s expertise in risk-based auditing and automation via robotics process automation aims to boost audit quality and operational efficiency, supporting stronger internal controls and process optimization.